Prospective, multicenter, randomized phase III trial evaluating the impact of lymphoscintigraphy as part of sentinel node biopsy in early breast cancer: SenSzi (GBG80) Trial

PURPOSEThe aim of the current work was to clarify whether a preoperative lymphoscintigraphy (LSG) enhances staging accuracy of sentinel lymph node biopsy (SLNB).PATIENTS AND METHODSIn a prospective, multicenter, randomized phase III trial, patients with cN0 early breast cancer or extensive/high-grad...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Kümmel, Sherko (VerfasserIn) , Holtschmidt, Johannes Claus (VerfasserIn) , Gerber, Bernd (VerfasserIn) , Assen, Albert von der (VerfasserIn) , Heil, Jörg (VerfasserIn) , Thill, Marc (VerfasserIn) , Krug, David (VerfasserIn) , Schem, Christian (VerfasserIn) , Denkert, Carsten (VerfasserIn) , Lubitz, Juliane (VerfasserIn) , Blohmer, Jens-Uwe (VerfasserIn) , Reinisch, Mattea (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: May 01, 2019
In: Journal of clinical oncology
Year: 2019, Jahrgang: 37, Heft: 17, Pages: 1490-1498
ISSN:1527-7755
DOI:10.1200/JCO.18.02092
Online-Zugang:Verlag, Volltext: https://doi.org/10.1200/JCO.18.02092
Verlag: https://ascopubs.org/doi/10.1200/JCO.18.02092
Volltext
Verfasserangaben:Sherko Kuemmel, Johannes Holtschmidt, Bernd Gerber, Albert Von der Assen, Joerg Heil, Marc Thill, David Krug, Christian Schem, Carsten Denkert, Juliane Lubitz, Jens Uwe Blohmer, Mattea Reinisch, Michael Hötzeldt, Fenja Seither, Valentina Nekljudova, Ilka Schwidde, Klara Uhrhan, Gunter Von Minckwitz, Mahdi Rezai, Jana Mulowski, Sibylle Loibl, Thorsten Kuehn

MARC

LEADER 00000caa a2200000 c 4500
001 1681501864
003 DE-627
005 20220817021642.0
007 cr uuu---uuuuu
008 191108s2019 xx |||||o 00| ||eng c
024 7 |a 10.1200/JCO.18.02092  |2 doi 
035 |a (DE-627)1681501864 
035 |a (DE-599)KXP1681501864 
035 |a (OCoLC)1341250587 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Kümmel, Sherko  |d 1971-  |e VerfasserIn  |0 (DE-588)122704142  |0 (DE-627)082103372  |0 (DE-576)293388016  |4 aut 
245 1 0 |a Prospective, multicenter, randomized phase III trial evaluating the impact of lymphoscintigraphy as part of sentinel node biopsy in early breast cancer  |b SenSzi (GBG80) Trial  |c Sherko Kuemmel, Johannes Holtschmidt, Bernd Gerber, Albert Von der Assen, Joerg Heil, Marc Thill, David Krug, Christian Schem, Carsten Denkert, Juliane Lubitz, Jens Uwe Blohmer, Mattea Reinisch, Michael Hötzeldt, Fenja Seither, Valentina Nekljudova, Ilka Schwidde, Klara Uhrhan, Gunter Von Minckwitz, Mahdi Rezai, Jana Mulowski, Sibylle Loibl, Thorsten Kuehn 
264 1 |c May 01, 2019 
300 |a 9 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 08.11.2019 
520 |a PURPOSEThe aim of the current work was to clarify whether a preoperative lymphoscintigraphy (LSG) enhances staging accuracy of sentinel lymph node biopsy (SLNB).PATIENTS AND METHODSIn a prospective, multicenter, randomized phase III trial, patients with cN0 early breast cancer or extensive/high-grade ductal carcinoma in situ planned for standard radioactive-labeled colloid LSG with subsequent SLNB were randomly assigned 1:1 to receive SLNB either with knowledge of the LSG findings or without. As the false-negative rate of SLNB correlates with the number of resected sentinel lymph nodes (SLNs), our primary end point was the mean number of histologically detected SLNs per patient. One thousand one hundred two evaluable patients were necessary to demonstrate noninferiority of SLNB without LSG. Stratified one-sided 95% CI for the difference (without LSG − with LSG) in the mean number of histologically detected SLNs had to be greater than −0.27 (10% noninferiority margin). Stratification was performed according to tumor focality and trial site. Additional predefined secondary end points (rates of node-positive patients and of completion axillary lymph node dissection) were analyzed to rule out differences in the reliable detection of nodal metastases.RESULTSBetween May 2014 and October 2015, 1,198 patients were randomly assigned in 23 German and Swiss breast centers. Modified intention-to-treat analysis (n = 1,163) showed a mean number of histologically detected SLNs of 2.21 with LSG and 2.26 without LSG (difference 0.05; stratified 95% CI, −0.18 to infinity), thus establishing noninferiority of omitting preoperative LSG. Secondary end points displayed no statistically significant differences.CONCLUSIONWe show that SLNB is equally effective irrespective of the surgeon’s knowledge of preoperative LSG results. SLNB without LSG will speed up the preoperative workflow and reduce cost. 
700 1 |a Holtschmidt, Johannes Claus  |d 1979-  |e VerfasserIn  |0 (DE-588)142681164  |0 (DE-627)638458412  |0 (DE-576)332802779  |4 aut 
700 1 |a Gerber, Bernd  |d 1957-  |e VerfasserIn  |0 (DE-588)136713238  |0 (DE-627)585337608  |0 (DE-576)301234620  |4 aut 
700 1 |a Assen, Albert von der  |d 1953-  |e VerfasserIn  |0 (DE-588)11567182X  |0 (DE-627)69149844X  |0 (DE-576)290011191  |4 aut 
700 1 |a Heil, Jörg  |d 1978-  |e VerfasserIn  |0 (DE-588)132580187  |0 (DE-627)52396160X  |0 (DE-576)299238679  |4 aut 
700 1 |a Thill, Marc  |d 1969-  |e VerfasserIn  |0 (DE-588)120154129  |0 (DE-627)08048333X  |0 (DE-576)292066694  |4 aut 
700 1 |a Krug, David  |e VerfasserIn  |0 (DE-588)1062940202  |0 (DE-627)807054747  |0 (DE-576)420297944  |4 aut 
700 1 |a Schem, Christian  |d 1974-  |e VerfasserIn  |0 (DE-588)124076661  |0 (DE-627)085621986  |0 (DE-576)294009183  |4 aut 
700 1 |a Denkert, Carsten  |d 1969-  |e VerfasserIn  |0 (DE-588)118129929  |0 (DE-627)079261124  |0 (DE-576)291730604  |4 aut 
700 1 |a Lubitz, Juliane  |e VerfasserIn  |4 aut 
700 1 |a Blohmer, Jens-Uwe  |d 1962-  |e VerfasserIn  |0 (DE-588)122376641  |0 (DE-627)081907958  |0 (DE-576)293244227  |4 aut 
700 1 |a Reinisch, Mattea  |e VerfasserIn  |0 (DE-588)1158691483  |0 (DE-627)1020763825  |0 (DE-576)504303635  |4 aut 
773 0 8 |i Enthalten in  |t Journal of clinical oncology  |d Alexandria, Va. : American Society of Clinical Oncology, 1983  |g 37(2019), 17, Seite 1490-1498  |h Online-Ressource  |w (DE-627)313116962  |w (DE-600)2005181-5  |w (DE-576)090887018  |x 1527-7755  |7 nnas  |a Prospective, multicenter, randomized phase III trial evaluating the impact of lymphoscintigraphy as part of sentinel node biopsy in early breast cancer SenSzi (GBG80) Trial 
773 1 8 |g volume:37  |g year:2019  |g number:17  |g pages:1490-1498  |g extent:9  |a Prospective, multicenter, randomized phase III trial evaluating the impact of lymphoscintigraphy as part of sentinel node biopsy in early breast cancer SenSzi (GBG80) Trial 
856 4 0 |u https://doi.org/10.1200/JCO.18.02092  |x Verlag  |x Resolving-System  |3 Volltext 
856 4 0 |u https://ascopubs.org/doi/10.1200/JCO.18.02092  |x Verlag 
951 |a AR 
992 |a 20191108 
993 |a Article 
994 |a 2019 
998 |g 1062940202  |a Krug, David  |m 1062940202:Krug, David  |p 7 
998 |g 132580187  |a Heil, Jörg  |m 132580187:Heil, Jörg  |d 910000  |d 910400  |e 910000PH132580187  |e 910400PH132580187  |k 0/910000/  |k 1/910000/910400/  |p 5 
999 |a KXP-PPN1681501864  |e 3538575428 
BIB |a Y 
SER |a journal 
JSO |a {"person":[{"family":"Kümmel","display":"Kümmel, Sherko","given":"Sherko","role":"aut"},{"display":"Holtschmidt, Johannes Claus","family":"Holtschmidt","given":"Johannes Claus","role":"aut"},{"given":"Bernd","role":"aut","display":"Gerber, Bernd","family":"Gerber"},{"given":"Albert von der","role":"aut","family":"Assen","display":"Assen, Albert von der"},{"role":"aut","given":"Jörg","display":"Heil, Jörg","family":"Heil"},{"role":"aut","given":"Marc","display":"Thill, Marc","family":"Thill"},{"family":"Krug","display":"Krug, David","role":"aut","given":"David"},{"given":"Christian","role":"aut","display":"Schem, Christian","family":"Schem"},{"role":"aut","given":"Carsten","family":"Denkert","display":"Denkert, Carsten"},{"role":"aut","given":"Juliane","family":"Lubitz","display":"Lubitz, Juliane"},{"family":"Blohmer","display":"Blohmer, Jens-Uwe","given":"Jens-Uwe","role":"aut"},{"role":"aut","given":"Mattea","family":"Reinisch","display":"Reinisch, Mattea"}],"language":["eng"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"origin":[{"dateIssuedDisp":"May 01, 2019","dateIssuedKey":"2019"}],"note":["Gesehen am 08.11.2019"],"title":[{"subtitle":"SenSzi (GBG80) Trial","title_sort":"Prospective, multicenter, randomized phase III trial evaluating the impact of lymphoscintigraphy as part of sentinel node biopsy in early breast cancer","title":"Prospective, multicenter, randomized phase III trial evaluating the impact of lymphoscintigraphy as part of sentinel node biopsy in early breast cancer"}],"id":{"eki":["1681501864"],"doi":["10.1200/JCO.18.02092"]},"name":{"displayForm":["Sherko Kuemmel, Johannes Holtschmidt, Bernd Gerber, Albert Von der Assen, Joerg Heil, Marc Thill, David Krug, Christian Schem, Carsten Denkert, Juliane Lubitz, Jens Uwe Blohmer, Mattea Reinisch, Michael Hötzeldt, Fenja Seither, Valentina Nekljudova, Ilka Schwidde, Klara Uhrhan, Gunter Von Minckwitz, Mahdi Rezai, Jana Mulowski, Sibylle Loibl, Thorsten Kuehn"]},"physDesc":[{"extent":"9 S."}],"relHost":[{"corporate":[{"display":"American Society of Clinical Oncology","role":"isb"}],"titleAlt":[{"title":"official journal of the American Society of Clinical Oncology"},{"title":"JCO"},{"title":"Journal of clinical oncology legacy archive (ASCO)"}],"part":{"pages":"1490-1498","year":"2019","issue":"17","text":"37(2019), 17, Seite 1490-1498","volume":"37","extent":"9"},"language":["eng"],"disp":"Prospective, multicenter, randomized phase III trial evaluating the impact of lymphoscintigraphy as part of sentinel node biopsy in early breast cancer SenSzi (GBG80) TrialJournal of clinical oncology","type":{"media":"Online-Ressource","bibl":"periodical"},"title":[{"title":"Journal of clinical oncology","subtitle":"JCO : an American Society of Clinical Oncology journal","title_sort":"Journal of clinical oncology"}],"origin":[{"publisherPlace":"Alexandria, Va. ; Baltimore, Md. [u.a.]","publisher":"American Society of Clinical Oncology ; Lippincott Williams & Wilkins","dateIssuedKey":"1983","dateIssuedDisp":"1983-"}],"pubHistory":["1.1983 -"],"note":["Fortsetzung der Druck-Ausgabe","Gesehen am 22.05.23"],"id":{"issn":["1527-7755"],"zdb":["2005181-5"],"eki":["313116962"]},"physDesc":[{"extent":"Online-Ressource"}],"recId":"313116962"}],"recId":"1681501864"} 
SRT |a KUEMMELSHEPROSPECTIV0120